“…AD has been associated with atopic (asthma, allergic rhinitis) and non-atopic comorbidities including cutaneous and extra-cutaneous infections, mental health disorders (depression, anxiety, sleep disturbance), and autoimmune diseases (alopecia areata, intestinal bowel diseases) that could require concomitant administration of targeted pharmacotherapy including monoclonal antibodies [ 3 , 4 ]. However, the safety of combining dupilumab with other monoclonal antibodies for different therapeutic indication may be debated.…”